Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes - Trial NCT03191396
Access comprehensive clinical trial information for NCT03191396 through Pure Global AI's free database. This Phase 3 trial is sponsored by Novo Nordisk A/S and is currently Completed. The study focuses on Diabetes,Diabetes Mellitus, Type 2. Target enrollment is 577 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Novo Nordisk A/S
Timeline & Enrollment
Phase 3
Jun 27, 2017
Aug 13, 2018
Primary Outcome
Change in HbA1c
Summary
This study is conducted in Europe. The aim of the study is to compare the effect of
 semaglutide subcutaneous (s.c., under the skin) 1.0 mg once-weekly to liraglutide s.c.1.2 mg
 once-daily on blood sugar levels after 30 weeks of treatment in people with type 2 diabetes.
 The study will last approximately 9 months (37 weeks). Each participant will have 7 visits at
 the clinic and 3 phone calls with the study doctor. At the visits, participants will have a
 number of tests, for example: general health checks, blood samples, heart and eye checks etc.
 Participants will also fill in some forms about their health and satisfaction with their
 diabetes treatment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03191396
Non-Device Trial